Hematology
| 2 min read
Reistone announces first patient dosed in two Phase 2 global studies of SHR0302, a JAK1 inhibitor for ulcerative colitis and Crohn’s disease
| 3 min read
Company looks to advance its Reveal ctDNA 20 kits and AMP-based target enrichment system
| 3 min read
Arcus and Strata announce clinical development collaboration for AB122 and predictive biomarkers
| 2 min read
MI Transcriptome companion diagnostic test receives FDA Breakthrough Device Designation
| 10+ min read
Drilling to the core of life itself: Researchers go deep into the world of metabolomics to find new therapeutic possibilities with metabo-oncology
| 3 min read
CStone and Bayer look to evaluate PD-L1 monoclonal antibody CS1001 in combination with regorafenib
| 3 min read
Columbia University researchers try to assess why many kidney transplants fail, even when donors and recipients are thought to be well matched
| 3 min read
Scientists bioengineer human liver disease-mimicking organoids in the lab with the hopes of finding new treatments
| 3 min read
Darzalex Phase 3 MAIA study results, published in The New England Journal of Medicine, show combination therapy increases progression-free survival in newly diagnosed, transplant ineligible multiple myeloma patients
| 3 min read
The acquisition includes novel late-stage renal cell carcinoma candidate PT2977
| 3 min read
Aptevo advances bispecific candidates, sees encouraging preclinical data
| 2 min read
Celgene's ozanimod reduced the loss of grey matter volume in the brains of patients with relapsing multiple sclerosis, according to post-hoc analysis
